SPY072 TL1A Inhibitor: Proof-of-Mechanism in RA, But Subthreshold Monotherapy Efficacy Redirects Pipeline Toward Combination and Adjacent Indications

Spyre's SPY072 Shows Efficacy in RA, Shifts Monotherapy Focus

Spyre Therapeutics announced topline results from the RA sub-study of its Phase 2 SKYWAY basket trial evaluating SPY072. Both doses of SPY072 demonstrated statistically significant benefits compared to placebo on one or more of the primary (DAS28-CRP), key secondary (ACR20), and exploratory (ACR50) endpoints. SPY072 was well tolerated with a safety profile consistent with the TL1A class. While these results provide proof-of-mechanism for TL1A in RA and support its potential in other autoimmune diseases and as a combination component, they did not meet the company’s internal target to prioritize SPY072 as a monotherapy in rheumatoid arthritis.

• SPY072 demonstrated statistically significant benefits in the rheumatoid arthritis (RA) sub-study. The low dose achieved a significant benefit on the primary endpoint (change from baseline in DAS28-CRP) at Week 12. Nominally significant improvements were also observed for the high dose on ACR20 and the low dose on ACR50. These efficacy results were generally comparable between advanced-therapy-naïve and advanced-therapy-experienced patient subgroups.
• The safety profile of SPY072 was consistent with the TL1A class, showing good tolerability. Rates of adverse events were comparable between the active treatment group (27%) and placebo (36%), with most events being mild or moderate. Only one serious treatment-emergent adverse event occurred per arm, none of which were deemed drug-related. The most common adverse events were infections and infestations, occurring at similar rates in both groups.
• Despite the demonstrated efficacy and favorable safety, the results did not meet Spyre's internal threshold to prioritize SPY072 as a monotherapy for RA. However, the data reinforces the broad potential of Spyre's long-acting TL1A antibodies in other autoimmune diseases and as optimal components in combination therapies. The company anticipates further topline results for SPY072 in psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) in Q4 2026, and has initiated a combination trial in hidradenitis suppurativa (HS).

SPY072's SKYWAY-RA Phase 2 Topline Results in Rheumatoid Arthritis

Recent clinical evidence in rheumatoid arthritis spans a range of therapeutic mechanisms, from JAK inhibitors to TNF inhibitor comparators, offering new insights into treatment sequencing and long-term disease management. The studies below represent key datasets informing current and evolving RA treatment strategies.

The Unmet Needs Driving Spyre's RA Monotherapy Decision

Rheumatoid arthritis continues to present substantial therapeutic gaps despite the proliferation of biologic and targeted synthetic DMARDs. Recent literature highlights several discrete patient populations where current treatment paradigms fall critically short, informing the strategic rationale for next-generation monotherapy approaches such as those being pursued by Spyre.

• Difficult-to-Treat RA (D2T-RA): Affecting an estimated 11.7% of RA patients globally (95% CI: 9.5%–14.3%)—and rising to 13.2% among b/tsDMARD-treated populations—D2T-RA is characterized by markedly inferior outcomes on existing agents. In JAK inhibitor-treated cohorts, 6-month drug retention rates were significantly lower in D2T-RA versus non-D2T-RA patients (64.0% vs. 78.4%; p = 0.030), and CDAI low disease activity achievement was nearly halved (34% vs. 62.3%; p < 0.001), with no significant predictive factors identified for treatment response in this group.

• Poly-Refractory RA (pr-RA): A critical subset within D2T-RA, pr-RA patients exhibit rapid radiographic progression (≥5 mSvdH units/year) at twice the rate of other D2T-RA cases (50% vs. 19.4%; p = 0.048). Stricter failure-based definitions further delineate this population: D2T(3)-RA (≥3 b/tsDMARD failures) has a prevalence of 4.3% and D2T(4)-RA (≥4 failures) of 1.6%, representing a small but clinically urgent group requiring mechanistically novel interventions.

• Seronegative RA: Seronegative patients remain diagnostically and therapeutically underserved, as the 2010 ACR/EULAR classification criteria are less sensitive in this population and major RCTs have predominantly enrolled autoantibody-positive patients. Novel biomarker tools—including the SeNe test (97% specificity vs. OA; 95% CI: 95–99%) and its successor SeNe 2.0 (98% specificity vs. population controls)—are being developed to identify pre-symptomatic seronegative individuals at high RA risk, supporting earlier intervention and prevention trial recruitment.

• RA-Associated Interstitial Lung Disease (RA-ILD): RA-ILD remains a leading driver of RA-related mortality, with no meaningful decline in incidence despite overall reductions in extraarticular manifestations. Therapeutic options remain scarce, though individualized risk stratification is evolving—incorporating patient-level risk factors and genetic biomarkers such as MUC5B—alongside emerging clinical trials evaluating antifibrotic and targeted therapies.

• Pre-Symptomatic and At-Risk Populations: Growing interest in disease prevention has prompted trials targeting the pre-arthritis phase, though current prevention studies predominantly enroll autoantibody-positive individuals, potentially excluding a substantial seronegative at-risk segment and limiting the generalizability of preventive strategies.